The Priority Review

Clinical trials

Median progression free survival on olaparib was 16.2 months in relapsed ovarian cancer

Median progression free survival was 16.2 months with olaparib maintenance therapy in L-MOCA. Research teams now have outcome data for 224 treated participants in the single-arm study.

Machine-summarized from the primary sources listed below; not independently reported. How we use automation

Median progression free survival was 16.2 months with olaparib maintenance therapy in patients with platinum sensitive relapsed ovarian cancer, the study record shows. AstraZeneca's Phase 3 L-MOCA study now has outcome data for 224 treated participants in a single-arm trial after complete or partial response to platinum-based chemotherapy.

Median time-to-event outcomes in L-MOCA Median with 95% confidence interval, 224 participants 10 20 30 40 50 60 Months, median Progression free survival primary outcome 12.5 to 18.2 16.2 Time to first subsequent treatment or death secondary outcome 16.0 to 20.9 18.3 Time to second progression or death secondary outcome 26.2 to 32.8 29.4 Time to second subsequent treatment or death secondary outcome 30.3 to 41.4 34.0 Overall survival from the first olaparib dose to death from any cause 42.7 to 56.1 51.0 Each table includes 224 participants and an assessment period up to 79 months. The BRCA-mutated subgroup comprised 106 participants. Its median progression free survival was 20.1 months. From the trial registry record NCT03534453, results first posted November 16, 2026. The Priority Review.
Median time-to-event outcomes in L-MOCA Median with 95% confidence interval, 224 participants 10 20 30 40 50 60 Months, median Progression free survival primary outcome 12.5 to 18.2 16.2 Time to first subsequent treatment or death secondary outcome 16.0 to 20.9 18.3 Time to second progression or death secondary outcome 26.2 to 32.8 29.4 Time to second subsequent treatment or death secondary outcome 30.3 to 41.4 34.0 Overall survival from the first olaparib dose to death from any cause 42.7 to 56.1 51.0 Each table includes 224 participants and an assessment period up to 79 months. The BRCA-mutated subgroup comprised 106 participants. Its median progression free survival was 20.1 months. From the trial registry record NCT03534453, results first posted November 16, 2026. The Priority Review.

Why it matters

Lynparza is indicated for maintenance treatment of adults with deleterious or suspected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy, the supplied prescribing information states. The label directs selection using an FDA-approved companion diagnostic. L-MOCA enrolled patients with platinum sensitive relapsed disease and included participants with a BRCA mutation and participants with BRCA wild type status, the study record shows.

Progression free survival

November 16, 2026, is the results-first-posted date. The primary outcome table gives median progression free survival of 16.2 months, with a 95% confidence interval from 12.5 to 18.2 months, among 224 participants, the record reports.

The measure runs from the first olaparib dose until investigator-assessed disease progression under RECIST 1.1 or death from any cause without disease progression, whichever comes first. It applies regardless of withdrawal from therapy or receipt of another anticancer therapy before progression. The record lists assessment up to 79 months.

The BRCA-mutated subgroup comprised 106 participants. Its median progression free survival was 20.1 months, with a 95% confidence interval from 16.4 to 26.1 months, the record reports. The baseline table also lists 117 participants with BRCA wild type status and 1 whose BRCA status was not reported.

Overall survival and subsequent treatment

Median overall survival, measured from the first olaparib dose to death from any cause, was 51.0 months, with a 95% confidence interval from 42.7 to 56.1 months, the record shows.

The secondary outcome tables also report:

  • Time to second progression or death: median 29.4 months, with a 95% confidence interval from 26.2 to 32.8 months.
  • Time to first subsequent treatment or death: median 18.3 months, with a 95% confidence interval from 16.0 to 20.9 months.
  • Time to second subsequent treatment or death: median 34.0 months, with a 95% confidence interval from 30.3 to 41.4 months.

Each table includes 224 participants and an assessment period up to 79 months, the record states.

Participants and treatment

The trial was open-label, nonrandomized and single-arm. It enrolled 225 participants, of whom 224 received at least one dose and entered the full analysis set. All treated participants were female and Asian; their mean age was 55.3 years, with a standard deviation of 8.42, the record reports.

To enroll, participants needed high-grade serous or endometrioid epithelial ovarian cancer, including primary peritoneal or fallopian tube cancer, and at least 2 previous lines of platinum-containing therapy. Platinum sensitive disease meant progression at least 6 months after completion of the last platinum-based chemotherapy dose, the eligibility criteria state.

Participants received olaparib 300 mg orally twice daily. The protocol called for clinical and radiological tumor assessments at baseline and every 12 weeks until objective radiological disease progression. Previous treatment with a PARP inhibitor, including olaparib, was an exclusion criterion, the record states.

Safety

Serious adverse events affected 61 of 224 participants in the safety table, which covers informed consent through the end of the study, up to 79 months. The table lists anemia among serious adverse events in 25 participants and myelosuppression in 7, the record reports.

Sources